133 related articles for article (PubMed ID: 10999467)
1. Discovery of a new class of p38 kinase inhibitors.
Dumas J; Sibley R; Riedl B; Monahan MK; Lee W; Lowinger TB; Redman AM; Johnson JS; Kingery-Wood J; Scott WJ; Smith RA; Bobko M; Schoenleber R; Ranges GE; Housley TJ; Bhargava A; Wilhelm SM; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2047-50. PubMed ID: 10999467
[TBL] [Abstract][Full Text] [Related]
2. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
[TBL] [Abstract][Full Text] [Related]
3. p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
Redman AM; Johnson JS; Dally R; Swartz S; Wild H; Paulsen H; Caringal Y; Gunn D; Renick J; Osterhout M; Kingery-Wood J; Smith RA; Lee W; Dumas J; Wilhelm SM; Housley TJ; Bhargava A; Ranges GE; Shrikhande A; Young D; Bombara M; Scott WJ
Bioorg Med Chem Lett; 2001 Jan; 11(1):9-12. PubMed ID: 11140741
[TBL] [Abstract][Full Text] [Related]
4. Pyridinylimidazole based p38 MAP kinase inhibitors.
Jackson PF; Bullington JL
Curr Top Med Chem; 2002 Sep; 2(9):1011-20. PubMed ID: 12171568
[TBL] [Abstract][Full Text] [Related]
5. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue.
Mavunkel BJ; Chakravarty S; Perumattam JJ; Luedtke GR; Liang X; Lim D; Xu YJ; Laney M; Liu DY; Schreiner GF; Lewicki JA; Dugar S
Bioorg Med Chem Lett; 2003 Sep; 13(18):3087-90. PubMed ID: 12941340
[TBL] [Abstract][Full Text] [Related]
6. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
[TBL] [Abstract][Full Text] [Related]
7. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.
Mclay LM; Halley F; Souness JE; McKenna J; Benning V; Birrell M; Burton B; Belvisi M; Collis A; Constan A; Foster M; Hele D; Jayyosi Z; Kelley M; Maslen C; Miller G; Ouldelhkim MC; Page K; Phipps S; Pollock K; Porter B; Ratcliffe AJ; Redford EJ; Webber S; Slater B; Thybaud V; Wilsher N
Bioorg Med Chem; 2001 Feb; 9(2):537-54. PubMed ID: 11249145
[TBL] [Abstract][Full Text] [Related]
8. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
Cirillo PF; Pargellis C; Regan J
Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
[TBL] [Abstract][Full Text] [Related]
9. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
[TBL] [Abstract][Full Text] [Related]
10. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
[TBL] [Abstract][Full Text] [Related]
11. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
[TBL] [Abstract][Full Text] [Related]
13. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
McKenna JM; Halley F; Souness JE; McLay IM; Pickett SD; Collis AJ; Page K; Ahmed I
J Med Chem; 2002 May; 45(11):2173-84. PubMed ID: 12014955
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.
Dumas J; Hatoum-Mokdad H; Sibley RN; Smith RA; Scott WJ; Khire U; Lee W; Wood J; Wolanin D; Cooley J; Bankston D; Redman AM; Schoenleber R; Caringal Y; Gunn D; Romero R; Osterhout M; Paulsen H; Housley TJ; Wilhelm SM; Pirro J; Chien DS; Ranges GE; Shrikhande A; Muzsi A; Bortolon E; Wakefield J; Gianpaolo Ostravage C; Bhargava A; Chau T
Bioorg Med Chem Lett; 2002 Jun; 12(12):1559-62. PubMed ID: 12039561
[TBL] [Abstract][Full Text] [Related]
15. SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors.
Liu L; Stelmach JE; Natarajan SR; Chen MH; Singh SB; Schwartz CD; Fitzgerald CE; O'Keefe SJ; Zaller DM; Schmatz DM; Doherty JB
Bioorg Med Chem Lett; 2003 Nov; 13(22):3979-82. PubMed ID: 14592489
[TBL] [Abstract][Full Text] [Related]
16. Successful screening of large encoded combinatorial libraries leading to the discovery of novel p38 MAP kinase inhibitors.
Metzger A; Diller DJ; Lin TH; Henderson I; Webb ML
Comb Chem High Throughput Screen; 2006 Jun; 9(5):351-8. PubMed ID: 16787148
[TBL] [Abstract][Full Text] [Related]
17. Pyridazine based inhibitors of p38 MAPK.
McIntyre CJ; Ponticello GS; Liverton NJ; O'Keefe SJ; O'Neill EA; Pang M; Schwartz CD; Claremon DA
Bioorg Med Chem Lett; 2002 Feb; 12(4):689-92. PubMed ID: 11844702
[TBL] [Abstract][Full Text] [Related]
18. Ones, thiones, and N-oxides: an exercise in imidazole chemistry.
Laufer S; Wagner G; Kotschenreuther D
Angew Chem Int Ed Engl; 2002 Jul; 41(13):2290-3. PubMed ID: 12203569
[No Abstract] [Full Text] [Related]
19. p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.
Natarajan SR; Wisnoski DD; Singh SB; Stelmach JE; O'Neill EA; Schwartz CD; Thompson CM; Fitzgerald CE; O'Keefe SJ; Kumar S; Hop CE; Zaller DM; Schmatz DM; Doherty JB
Bioorg Med Chem Lett; 2003 Jan; 13(2):273-6. PubMed ID: 12482438
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
